









Markets
/
Stocks
/
nasdaq-asrt
/

Assertio Holdings Inc

ASRT

12.740USD

+1.120+9.64%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

81.75MMarket Cap

LossP/E TTM



Assertio Holdings Inc

12.740

+1.120+9.64%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Assertio Holdings Inc

Currency: USD Updated: 2026-02-06

Key Insights

Assertio Holdings Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 75 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 37.44.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Assertio Holdings Inc's Score

Industry at a Glance

Industry Ranking

75 / 159

Overall Ranking

195 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Assertio Holdings Inc Highlights

StrengthsRisks

Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.

Undervalued

The company’s latest PE is -2.81, at a low 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 297.25K shares of this stock.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

37.438

Target Price

+222.18%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Assertio Holdings Inc is 8.15, ranking 83 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 49.46M, representing a year-over-year increase of 69.36%, while its net profit experienced a year-over-year increase of 491.82%.

Score

Industry at a Glance

Previous score

8.15

Change



Financials

6.44

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.66

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Assertio Holdings Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Assertio Holdings Inc is 6.33, ranking 126 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -2.81, which is -232.04% below the recent high of 3.71 and -1070.34% above the recent low of -32.90.

Score

Industry at a Glance

Previous score

6.33

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 75/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Assertio Holdings Inc is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 3.00, with a high of 3.00 and a low of 1.65.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

37.438

Target Price

+222.18%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Assertio Holdings Inc

ASRT

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Assertio Holdings Inc is 9.69, ranking 11 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 14.09 and the support level at 10.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.30

Change

0.39

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.148

Buy

RSI(14)

66.123

Neutral

STOCH(KDJ)(9,3,3)

67.406

Buy

ATR(14)

0.713

Low Volatility

CCI(14)

170.351

Buy

Williams %R

10.995

Overbought

TRIX(12,20)

0.738

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

12.088

Buy

MA10

12.013

Buy

MA20

11.406

Buy

MA50

10.947

Buy

MA100

10.321

Buy

MA200

5.511

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Assertio Holdings Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 41.62%, representing a quarter-over-quarter decrease of 17.33%. The largest institutional shareholder is The Vanguard, holding a total of 297.25K shares, representing 4.63% of shares outstanding, with 1.19% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Nantahala Capital Management, LLC

587.34K

The Vanguard Group, Inc.

Star Investors

295.04K

+0.94%

Renaissance Technologies LLC

Star Investors

196.15K

+4.26%

BlackRock Institutional Trust Company, N.A.

90.98K

-0.72%

Geode Capital Management, L.L.C.

68.15K

+0.09%

Two Sigma Investments, LP

53.26K

-7.94%

Polen Capital Management, LLC

52.07K

-43.40%

CM Management, LLC

48.29K

Peisert (Daniel A)

40.50K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Assertio Holdings Inc is 1.43, ranking 152 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.73. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.